Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Mechlorethamine
Drug ID BADD_D01359
Description A vesicant and necrotizing irritant destructive to mucous membranes, mechlorethamine is an alkylating drug. It was formerly used as a war gas. The hydrochloride is used as an antineoplastic in Hodgkin's disease and lymphomas. It causes severe gastrointestinal and bone marrow damage. The FDA granted marketing approval for the orphan drug Valchlor (mechlorethamine) gel on August 23, 2013 for the topical treatment of stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma (CTCL) in patients who have received prior skin-directed therapy. Each tube of Valchlor contains 0.016% of mechlorethamine which is equivalent to 0.02% mechlorethamine HCl.
Indications and Usage For the palliative treatment of Hodgkin's disease (Stages III and IV), lymphosarcoma, chronic myelocytic or chronic lymphocytic leukemia, polycythemia vera, mycosis fungoides, and bronchogenic carcinoma. Also for the palliative treatment of metastatic carcinoma resulting in effusion.
Marketing Status Prescription
ATC Code L01AA05
DrugBank ID DB00888
KEGG ID D07671
MeSH ID D008466
PubChem ID 4033
TTD Drug ID D03SSE
NDC Product Code Not Available
Synonyms Mechlorethamine | Chlormethine | Bis(2-chloroethyl)methylamine | Mustine | Nitrogen Mustard | Chlorethazine | Methylchlorethamine | Cloramin | Embichin | Mechlorethamine Hydrochloride | Hydrochloride, Mechlorethamine | Mechlorethamine Hydrochloride N-Oxide | Hydrochloride N-Oxide, Mechlorethamine | Mechlorethamine Hydrochloride N Oxide | N-Oxide, Mechlorethamine Hydrochloride | NSC-762 | NSC 762 | NSC762 | Mechlorethamine Oxide | Mitomen | Mustargen | Nitrogranulogen | Nitromin | NSC-10107 | NSC 10107 | NSC10107 | Caryolysine | Mechlorethamine N-Oxide | Mechlorethamine N Oxide | Nitrogen Mustard N-Oxide | N-Oxide, Nitrogen Mustard | Nitrogen Mustard N Oxide
Chemical Information
Molecular Formula C5H11Cl2N
CAS Registry Number 51-75-2
SMILES CN(CCCl)CCCl
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Pneumonia22.07.01.003; 11.01.09.003--Not Available
Pruritus23.03.12.0010.031170%
Pyrexia08.05.02.003--
Rash23.03.13.0010.010124%Not Available
Rash erythematous23.03.06.0030.001332%Not Available
Rash generalised23.03.13.0020.000799%Not Available
Rash macular23.03.13.0030.001066%Not Available
Rash papular23.03.13.0170.002398%Not Available
Rash pruritic23.03.12.0020.001598%Not Available
Respiratory disorder22.02.07.0020.000799%Not Available
Scab23.03.03.0040.003197%Not Available
Sinusitis11.01.13.005; 22.07.03.0070.000533%
Skin atrophy23.01.05.0010.000799%
Skin cancer16.03.02.002; 23.08.02.002--Not Available
Skin discolouration23.03.03.0050.013853%Not Available
Skin disorder23.03.03.0070.002931%Not Available
Skin erosion23.07.03.0020.002131%Not Available
Skin exfoliation23.03.07.0030.004529%Not Available
Skin fissures23.03.03.0080.001865%Not Available
Skin hyperpigmentation23.05.01.0030.003996%
Skin hypertrophy23.01.04.0020.000799%Not Available
Skin infection23.09.04.002; 11.01.12.0030.000799%
Skin irritation23.03.04.0090.013321%Not Available
Skin lesion23.03.03.0100.004263%Not Available
Skin reaction23.03.03.013; 10.01.03.0190.001598%Not Available
Skin ulcer24.04.03.007; 23.07.03.0030.000486%
Skin warm23.03.03.0140.000799%Not Available
Sleep disorder19.02.04.0010.000533%Not Available
Superior vena cava syndrome24.04.09.008; 16.32.03.019--
Swelling08.01.03.0150.001598%Not Available
The 4th Page    First    Pre   4 5 6    Next   Last    Total 6 Pages